Latest Thalidomide Stories
ROCKVILLE, Md., Dec.
SAN FRANCISCO, Dec.
The International Myeloma Foundation (IMF)--supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians--today called for all patients to have access to the newest pharmaceuticals making life-changing advances in the treatment of myeloma.
Revlimid has become the latest in a series of oncology drugs that have failed to satisfy NICE's cost-effectiveness criteria. As a result, Celgene's drug will not be available to multiple myeloma patients on the UK's National Health Service.
Celgene and Acceleron Pharma have initiated a Phase II clinical study of its lead compound ACE-011 in patients with multiple myeloma. Celgene will make a $5 million milestone payment to Acceleron in accordance with the terms of the collaboration agreement between the two companies.
Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the initiation of a Phase 2 clinical study of its lead compound ACE-011 in patients with multiple myeloma.
Celgene International, a wholly owned subsidiary of Celgene Corporation, has announced that its oral cancer drug Revlimid has received marketing authorization approval from Health Canada for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.
Tokyo, Oct. 3 (Jiji Press)--A Japanese Health, Labor and Welfare Ministry panel on Friday approved the production and sale of thalidomide, a controversial sedative-hypnotic banned more than 40 years ago, for the treatment of multiple myeloma, a type of blood cancer, under strict conditions.
The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy, and support for myeloma patients, families, researchers, and physicians - today heralded the expansion of treatment options for previously untreated patients with multiple myeloma, giving patients in Canada and Europe access to drugs similar to what is available to patients in the United States.
By Jones, D Beyond Thalidomide: Birth defects explained. Edited by J. McCredie Pp. 418. Royal Society of Medicine Press Ltd. 2007. ISBN: 13: 978-1-85315-741-7. Pounds 35.
- A gift; a largess; a gratuity; a present; a dole.